TET2 and mature T-cell and NK-cell non-Hodgkin lymphoma: Recent research has begun to explore the efficacy of azacytidine, alone or in combination with other therapies, in improving responses in PTCL, especially in cases expressing T-follicular helper cell markers or harboring mutations like TET2 [7].